Brasó-Maristany, Fara
Griguolo, Gaia
Pascual, Tomás http://orcid.org/0000-0001-8431-3183
Paré, Laia
Nuciforo, Paolo http://orcid.org/0000-0003-1380-0990
Llombart-Cussac, Antonio
Bermejo, Begoña
Oliveira, Mafalda http://orcid.org/0000-0001-9152-8799
Morales, Serafín
Martínez, Noelia
Vidal, Maria
Adamo, Barbara
Martínez, Olga http://orcid.org/0000-0001-8686-0236
Pernas, Sonia
López, Rafael
Muñoz, Montserrat
Chic, Núria
Galván, Patricia
Garau, Isabel
Manso, Luis
Alarcón, Jesús
Martínez, Eduardo
Gregorio, Sara
Gomis, Roger R. http://orcid.org/0000-0001-6473-2858
Villagrasa, Patricia
Cortés, Javier
Ciruelos, Eva
Prat, Aleix
Funding for this research was provided by:
Breast Cancer Now (2018NOVPCC1294)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI16/00904)
Fundación Científica Asociación Española Contra el Cáncer - Ayuda Postdoctoral AECC 2017 (to F. B-M). Pas a Pas (to A.P.) Save the Mama
Article History
Received: 18 July 2019
Accepted: 16 December 2019
First Online: 20 January 2020
Competing interests
: A.P. reports consulting fees from Nanostring Technologies Roche, Pfizer, Novartis and Daiichi Sankyo outside the submitted work. G.G. reports travel support from Pfizer. M.O. reports grant support (to the Institution) from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer-Ingelheim, PUMA Biotechnology, consultant fees from Roche, GSK, PUMA Biotechnology and honoraria from Roche, Novartis and travel grants from Roche, Pierre-Fabre, Novartis, GP Pharma, Grünenthal outside the submitted work. S.P. has received honoraria for travel grants from Roche and has served as an advisor/consultant to Polyphor outside of the submitted work. N.M. is a speaker honorarium from AstraZeneca, Roche, Novartis, Celgene, Eisai, and Pfizer outside the submitted work. E.C. reports personal fees from Roche, Lilly, Pfizer and Novartis outside the submitted work. The remaining authors declare no competing interests.